1.Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach [https://www.who.int/hiv/pub/arv/arv–2016/en/]
2.McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, Sullivan AK, Clarke A, Reeves I, Schembri G et al: Pre-exposure prophylaxis to prevent the acquisition of HIV–1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016, 387(10013):53–60.
3.Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapia M, Guanira-Carranza JV, Ramirez-Cardich ME et al: Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010, 363(27):2587–2599.
4.Dehne KL, Dallabetta G, Wilson D, Garnett GP, Laga M, Benomar E, Fakoya A, Baggaley RC, Nelson LJ, Kasedde S et al: HIV Prevention 2020: a framework for delivery and a call for action. Lancet HIV 2016, 3(7):e323–332.
5.Zhang L, Peng P, Wu Y, Ma X, Soe NN, Huang X, Wu H, Markowitz M, Meyers K: Modelling the Epidemiological Impact and Cost-Effectiveness of PrEP for HIV Transmission in MSM in China. AIDS Behav 2018.
6.Mao X, Yu H, Hu QH, Zhang J, Chu ZX, Wang YN, Geng WQ, Jiang YJ, Xu JJ: [Acceptability of pre-exposure HIV prophylaxis clinical trial among MSM in Shenyang city]. Zhonghua Liu Xing Bing Xue Za Zhi 2017, 38(8):1083–1087.
7.Xue H, Liu H, Cai L: [Analysis of willingness and influencing factors for usage of pre-exposure prophylaxis among men who have sex with men]. Zhonghua Yu Fang Yi Xue Za Zhi 2015, 49(11):973–977.
8.Zhou F, Gao L, Li S, Li D, Zhang L, Fan W, Yang X, Yu M, Xiao D, Yan L et al: Willingness to accept HIV pre-exposure prophylaxis among Chinese men who have sex with men. PLoS One 2012, 7(3):e32329.
9.Liu C, Ding Y, Ning Z, Gao M, Liu X, Wong FY, He N: Factors influencing uptake of pre-exposure prophylaxis: some qualitative insights from an intervention study of men who have sex with men in China. Sexual health 2018, 15(1):39–45.
10.Qu D, Zhong X, Xiao G, Dai J, Liang H, Huang A: Adherence to pre-exposure prophylaxis among men who have sex with men: A prospective cohort study. Int J Infect Dis 2018, 75:52–59.
11.Jackson T, Huang A, Chen H, Gao X, Zhong X, Zhang Y: Cognitive, psychosocial, and sociodemographic predictors of willingness to use HIV pre-exposure prophylaxis among Chinese men who have sex with men. AIDS Behav 2012, 16(7):1853–1861.
12.Zhang Y, Peng B, She Y, Liang H, Peng HB, Qian HZ, Vermund SH, Zhong XN, Huang A: Attitudes toward HIV pre-exposure prophylaxis among men who have sex with men in western China. AIDS Patient Care STDS 2013, 27(3):137–141.
13.Wei C, Raymond HF: Pre-exposure prophylaxis for men who have sex with men in China: challenges for routine implementation. J Int AIDS Soc 2018, 21(7):e25166.
14.Tatham LM, Savage AC, Dwyer A, Siccardi M, Scott T, Vourvahis M, Clark A, Rannard SP, Owen A: Towards a Maraviroc long-acting injectable nanoformulation. Eur J Pharm Biopharm 2019, 138:92–98.
15.Schlesinger E, Johengen D, Luecke E, Rothrock G, McGowan I, van der Straten A, Desai T: A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis. Pharm Res 2016, 33(7):1649–1656.
16.Meyers K, Wu Y, Qian H, Sandfort T, Huang X, Xu J, Zhang J, Xia W, Glidden D, Wu H et al: Interest in Long-Acting Injectable PrEP in a Cohort of Men Who have Sex with Men in China. AIDS Behav 2018, 22(4):1217–1227.
17.Parsons JT, Rendina HJ, Whitfield TH, Grov C: Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S. AIDS Behav 2016, 20(7):1390–1399.
18.Ding Y, Yan H, Ning Z, Cai X, Yang Y, Pan R, Zhou Y, Zheng H, Gao M, Rou K et al: Low willingness and actual uptake of pre-exposure prophylaxis for HIV–1 prevention among men who have sex with men in Shanghai, China. Biosci Trends 2016, 10(2):113–119.
19.Wang Z, Lau JTF, Fang Y, Ip M, Gross DL: Prevalence of actual uptake and willingness to use pre-exposure prophylaxis to prevent HIV acquisition among men who have sex with men in Hong Kong, China. PLoS One 2018, 13(2):e0191671.
20.Shan J: Gay men find HIV drug in Thailand, not China. In: China Daily. 2017.
21.Pan SW, Durvasula M, Ong JJ, Liu C, Tang W, Fu H, Wei C, Wang C, Terris-Prestholt F, Tucker JD: No Place Like Home? Disentangling Preferences for HIV Testing Locations and Services Among Men Who Have Sex with Men in China. AIDS Behav 2018.
22.Zhang TP, Liu C, Han L, Tang W, Mao J, Wong T, Zhang Y, Tang S, Yang B, Wei C: Community engagement in sexual health and uptake of HIV testing and syphilis testing among MSM in China: a cross-sectional online survey. Journal of the International AIDS Society 2017, 20(1).
23.Oldenburg CE, Le B, Huyen HT, Thien DD, Quan NH, Biello KB, Nunn A, Chan PA, Mayer KH, Mimiaga MJ et al: Antiretroviral pre-exposure prophylaxis preferences among men who have sex with men in Vietnam: results from a nationwide cross-sectional survey. Sex Health 2016.
24.Mosley T, Khaketla M, Armstrong HL, Cui Z, Sereda P, Lachowsky NJ, Hull MW, Olarewaju G, Jollimore J, Edward J et al: Trends in Awareness and Use of HIV PrEP Among Gay, Bisexual, and Other Men who have Sex with Men in Vancouver, Canada 2012–2016. AIDS Behav 2018, 22(11):3550–3565.
25.Strauss BB, Greene GJ, Phillips G, 2nd, Bhatia R, Madkins K, Parsons JT, Mustanski B: Exploring Patterns of Awareness and Use of HIV Pre-Exposure Prophylaxis Among Young Men Who Have Sex with Men. AIDS Behav 2017, 21(5):1288–1298.
26.Hoagland B, De Boni RB, Moreira RI, Madruga JV, Kallas EG, Goulart SP, Cerqueira N, Torres TS, Luz PM, Fernandes NM et al: Awareness and Willingness to Use Pre-exposure Prophylaxis (PrEP) Among Men Who Have Sex with Men and Transgender Women in Brazil. AIDS Behav 2017, 21(5):1278–1287.
27.Biello KB, Edeza A, Montgomery MC, Almonte A, Chan PA: Risk Perception and Interest in HIV Pre-exposure Prophylaxis Among Men Who Have Sex with Men with Rectal Gonorrhea and Chlamydia Infection. Arch Sex Behav 2018.
28.Preexpo ure Prophylaxi for the Prevention of HIV Infection in the United State—2017 Update Clinical Practice Guideline [https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines–2017.pdf]
29.Molina JM, Charreau I, Spire B, Cotte L, Chas J, Capitant C, Tremblay C, Rojas-Castro D, Cua E, Pasquet A et al: Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV 2017, 4(9):e402-e410.
30.Meyers K, Rodriguez K, Moeller RW, Gratch I, Markowitz M, Halkitis PN: High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy. PLoS One 2014, 9(12):e114700.
31.Van der Elst EM, Mbogua J, Operario D, Mutua G, Kuo C, Mugo P, Kanungi J, Singh S, Haberer J, Priddy F et al: High acceptability of HIV pre-exposure prophylaxis but challenges in adherence and use: qualitative insights from a phase I trial of intermittent and daily PrEP in at-risk populations in Kenya. AIDS Behav 2013, 17(6):2162–2172.
32.Fisher CB, Fried AL, Ibrahim Puri L, Macapagal K, Mustanski B: “Free Testing and PrEP without Outing Myself to Parents:” Motivation to participate in oral and injectable PrEP clinical trials among adolescent men who have sex with men. PLoS One 2018, 13(7):e0200560.
33.Cahill S, Taylor SW, Elsesser SA, Mena L, Hickson D, Mayer KH: Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts. AIDS Care 2017, 29(11):1351–1358.
34.Liu Y, Osborn CY, Qian HZ, Yin L, Xiao D, Ruan Y, Simoni JM, Zhang X, Shao Y, Vermund SH et al: Barriers and Facilitators of Linkage to and Engagement in HIV Care Among HIV-Positive Men Who Have Sex with Men in China: A Qualitative Study. AIDS Patient Care STDS 2016, 30(2):70–77.